Clinical and Laboratory Predictors of COVID-19-Related In-hospital Mortality; a Cross-sectional Study of 1000 Cases

Zohreh Mohammadi\(^1\), Masood Faghih Dinevari\(^2\), Nafiseh Vahed\(^3\), Hanleyh Ebrahim Bakhtavar\(^1\), Farzad Rahmani\(^4\)*

1. Emergency and Trauma Care Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2. Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3. Research Center for Evidence-Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
4. Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran.

Received: April 2022; Accepted: May 2022; Published online: 23 June 2022

Abstract: Introduction: Identifying patients at risk for mortality and using appropriate treatment for each patient based on their situation could be an effective strategy in improving their outcome. This study aimed to evaluated the predictors of COVID-19 in-hospital mortality. Methods: This descriptive cross-sectional study was conducted on all adult COVID-19 patients who were managed in Imam-Reza and Sina Hospitals, Tabriz, Iran, from November 2020 until December 2021. The demographic, clinical, and laboratory characteristics of patients were evaluated and predictors of in-hospital mortality were identified using logistic regression model. Results: 1000 patients with the mean age of 56.34 ± 18.00 years were studied (65.7% male). There were significant associations between COVID-19 in-hospital mortality and hospitalization above five days (p = 0.001), white blood cell count (WBC) > 4000 Cells*10\(^3\)/mL (p < 0.01), aspartate aminotransferase (AST) above 40 IU/L (p = 0.001), alanine transaminase (ALT) above 40 IU/L (p = 0.001), creatinine above 1.4 mg/dL (p = 0.007), urea above 100 mg/dL (p = 0.024), and SaO\(_2\) below 80% (p = 0.001). Hospital stay above five days (OR: 3.473; 95%CI: 1.272 - 9.479; p = 0.15), AST above 40 IU/L (OR: 0.269, 95%CI: 0.179 - 0.402; p = 0.001), creatinine above 1.4 mg/dL (OR: 0.529; 95%CI: 0.344 - 0.813; p = 0.004), urea above 100 mg/dL (OR: 0.327, 95%CI: 0.189 - 0.567; p = 0.001), and SaO\(_2\) below 80% (OR: 8.754, 95%CI: 5.413 - 14.156; p = 0.001) were among the independent predictors of COVID-19 in-hospital mortality. Conclusion: The mortality rate of patients with COVID-19 in our study was 29.9%. Hospitalization of more than five days, AST above 40 IU/L, creatinine above 1.4 mg/dL, urea above 100 mg/dL and SaO\(_2\) < 80% were independent risk factors of in-hospital mortality among patients with COVID-19.

Keywords: COVID-19; Mortality; Prognosis; Respiratory Distress Syndrome

1. Introduction

In December 2019, patients were diagnosed with pneumonia of unknown origin, later known as SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus 2), in Wuhan, China (1, 2). The clinical manifestation of SARS-CoV-2 infection is mutable and includes asymptomatic disease, upper respiratory tract disorders, and in some cases, acute and severe fatal conditions. Therefore, to summarize the clinical manifestations and widespread consequences of SARS-CoV-2 infections, the WHO chose the specific name COVID-19 (Coronavirus disease 2019) for this disease (3-5). The mortality rate is the most crucial factor in turning an infection into a public concern and the risk of developing a pandemic. Different viruses become epidemics each year, but very few of them become a public concern (6-8). Swine influenza A (H1N1 virus), severe acute respiratory syndrome...
(SARS), and Ebola (Zaire ebolavirus) have led to global concern in recent years due to high mortality (9, 10). As in the above cases, COVID-19 has received all the attention and has caused concern due to its high mortality rate (3, 11). For example, although the flu is widespread, its mortality rate is only 0.1%. Reports have also shown that COVID-19 is highly contagious and can spread via various routes (3, 5, 12).

The rate of infectivity is a significant factor, but the mortality rate from COVID-19 is not correctly estimated. Because when the initial mortality rate is reported, only patients with very severe condition are in the statistical population, and patients with mild to moderate disease are not included in the investigation (12). The rapid development of COVID-19 in Wuhan, China, has resulted in thousands of deaths (13), and the widespread virus worldwide has resulted in hundreds of thousands of patients (14). In Iran, WHO reports that there were about 10000 new cases of COVID-19 per day during the study, and death rate was about 400 cases daily (15). More deaths were observed in patients with severe disease, and other patients in whom the disease symptoms were flu-like, improved quickly, and returned to everyday life (5). In addition, the difference between the clinical features of patients with severe and non-severe diseases has been rarely reported (16, 17). Also, in some studies, the clinical features of patients with severe diseases who died were compared with patients who survived after the infection. We hypothesized that assessing routine parameters such as vital signs and laboratory tests in COVID-19 patients, especially patients with severe disease, can help medical staff better manage patients. Therefore, this study aimed to design a predictive model of mortality in patients admitted with COVID-19, to identify patients with different conditions and use appropriate treatment for each patient based on their situation.

2. Methods

2.1. Study design and setting

This descriptive cross-sectional study was conducted with the approval of the institutional ethics committee at Tabriz University of Medical Sciences (IR.TBZMED.REC.1399.950) in two Medical Research, Training and Treatment General Hospitals, Imam-Reza and Sina Hospitals, Tabriz, Iran, from November 2020 until December 2021. The data of all adult COVID-19 patients admitted in the mentioned hospitals during the study period were evaluated and predictors of in-hospital mortality were determined using logistic regression model.

2.2. Participants

The study included patients older than 18 years, with COVID-19 pneumonia, confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV-2. The sampling method was a complete census. The minimum number of samples is 1000 patients. The sample size was estimated based on the COVID-19 prevalence of 33% (18), a confidence interval of 95%, and a relative estimation error of 10%. Exclusion criteria were incomplete information recorded in the patient’s medical record, discharge against medical advice, leaving the study in the middle of the study procedure, not willing to participate in the project, and negative PCR test (figure 1).

2.3. Data gathering

Patients’ demographic characteristics at the time of admission (age, sex, body mass index (BMI)), underlying disease, drug history, vital signs (blood pressure, heart rate (HR), respiration rate (RR), body temperature, O2 Saturation, AVPU level of consciousness), need for supplemental oxygen (via nasal cannula or mask), lung involvement on computed tomography (CT) scan, and the laboratory test results were recorded in the checklist. Laboratory findings included complete blood count (white blood cell (WBC), Neutrophil, Lymphocyte, Hemoglobin and Platelet counts), Liver functional enzymes (including Aspartate transaminase, Alanine transaminase, and Alkaline phosphatase), Creatinine, Urea, Coagulation status (including Prothrombin Time (PT), Partial Thromboplastin Time (PTT), and International Normalized Ratio (INR)), Venous blood gas analysis (including pH, PaCO2, and HCO3), and serum sodium (Na) and potassium (K) status. The patients were followed up during hospitalization (short-term follow-up of 30 days), and the duration...
Figure 2: Area under the receiver operating characteristic (ROC) curve of hospital stay above five days (P value: 0.435), aspartate aminotransferase (AST) above 40 IU/L (P value: 0.001), creatinine above 1.4 mg/dL (P value: 0.001), urea above 100 mg/dL (P value: 0.001), and SаO2 below 80% (P value: 0.001) in predicting the in-hospital mortality of COVID-19 patients.

of hospitalization, intubation, intensive care unit (ICU) hospitalization, and outcome, including death or survival, were assessed.

2.4. Outcome
The study's primary outcome was patient mortality during the hospitalization period or within 30 days from admission.

2.5. Statistical analysis
All data were entered into the SPSS 21. Normal data distribution was assessed using Kolmogorov-Smirnov test. For the descriptive data, mean ± standard deviation was used to report the findings in the case of normal data distribution. In case of non-normal data distribution, the median was used, and for qualitative variables frequency (percentage) was reported. The Independent sample's T-test was used to compare quantitative data if the data distribution was normal, and the Mann Whitney U test was used if it was non-normal. The Chi-square test was used to compare qualitative data. The receiver operating characteristic (ROC) curve was used to determine the predictive value of each of the studied variables. Area under the ROC curve (AUC), cut-off point, sensitivity, specificity, positive predictive value, negative predictive value, positive and negative likelihood ratios, and J point were reported. In all cases, a P value less than 0.05 was considered significant. Logistic regression and Odds Ratio were used to determine the value of each variable and their coefficients to create the model. The primary bias of the study was missing data, to address this problem we excluded patients with missing data. The comparison was made between patients who survived and those who died.

3. Results
3.1. Baseline and Clinical findings
1000 patients with the mean age of 56.34 ± 18.00 (range: 18 - 96) years were studied (65.7% male). The most frequent underlying disease was hypertension (32.2%). Of all patients, 29.9% died during admission. The demographic and clinical findings of the studied patients are compared between survived and non-survived cases in table 1. Results showed that the mean age of dead patients was significantly higher (59.36 ± 18.40 vs. 55.05 ± 17.68 years; p = 0.001), and the rate of mortality was significantly lower in females than in males.
(28.4% vs. 71.6%; p = 0.011). The mean HR (94.61 ± 91.41 vs. 65.34 ± 18.00, p = 0.001), WBC above 4000 Cells*10^3/mL (p < 0.01), AST above 40 IU/L (p = 0.001), ALT above 40 IU/L (p = 0.001), creatinine above 1.4 mg/dL (p = 0.007), urea above 100 mg/dL (p = 0.024), and SaO2 below 80% (p = 0.001) (table 3).

Based on the results of multivariate logistic regression analysis, hospital stay above five days (OR: 3.473; 95%CI: 1.272 - 9.479; p = 0.015), AST above 40 IU/L (OR: 0.269, 95%CI: 0.179 - 0.402; p = 0.001), creatinine above 1.4 mg/dL (OR: 0.529; 95%CI: 0.344 - 0.813; p = 0.004), urea above 100 mg/dL (OR: 0.327, 95%CI: 0.189 - 0.567; p = 0.001), and SaO2 below 80% (OR: 8.754, 95%CI: 5.413 - 14.156; p = 0.001) were among the independent predictors of COVID-19 in-hospital mortality (Table 4).

To evaluate the diagnostic value of independent risk factors of mortality, the ROC Curve analysis was used (Figure 2 and Table 5). SaO2 has an excellent diagnostic value for predicting in-hospital mortality of COVID-19 patients in cut-off point of 85.5% (67.7% sensitivity, and 56.3% specificity).

3.2. Laboratory findings

Laboratory and paraclinical findings of the patients are shown in Table 2. The results showed that the values of WBC (8.27 ± 7.71 vs. 7.53 ± 5.29 cells*10^3; p = 0.009), neutrophils (81.68 ± 8.90% vs. 78.93 ± 12.19%; p = 0.001), ALT (60.82 ± 66.04 vs. 46.11 ± 47.48 IU/L; p = 0.001), AST (56.46 ± 75.00 vs. 41.73 ± 38.55 IU/L; p = 0.001), creatinine (1.56 ± 1.34 vs. 1.23 ± 1.21 mg/dL; p = 0.001), and urea (62.85 ± 54.98 vs. 42.98 ± 32.62; p = 0.001) were significantly higher in dead patients.

3.3. Predictors of Mortality

There were significant associations between COVID-19 in-hospital mortality and hospitalization above five days (p = 0.001), WBC > 4000 Cells*10^3/mL (p < 0.01), AST above 40 IU/L (p = 0.001), ALT above 40 IU/L (p = 0.001), creatinine above 1.4 mg/dL (p = 0.007), urea above 100 mg/dL (p = 0.024), and SaO2 below 80% (p = 0.001) (table 3).

In this study, which was performed to design a prediction model for hospital mortality in admitted COVID-19 patients, 1000 patients who referred to Imam Reza and Sina Hospitals in Tabriz were studied. The mean age of the patients was 56.34 years, and 65.7% of the patients were male. The mortality rate was 29.9%. Evaluation of demographic character-
Table 2: Comparing the laboratory findings on admission between survived and non-survived cases

| Variable | Alive (n=701) | Dead (n=299) | Dead (n=1000) | P |
|----------|--------------|--------------|---------------|---|
| WBC (Cells*10^3/mL) | 7.53±5.29 | 8.27±7.71 | 7.75±6.12 | 0.009 |
| Neutrophil (%) | 78.93±12.19 | 81.68±9.90 | 79.75±11.62 | 0.001 |
| Lymphocyte (%) | 20.88±12.27 | 18.00±10.04 | 20.02±11.72 | 0.001 |
| Hb (g/dL) | 13.46±1.94 | 12.27±2.15 | 13.11±2.08 | 0.061 |
| Plt (Cells*10^3/mL) | 235.53±100.71 | 235.99±119.43 | 241.05±106.92 | 0.110 |
| AST (IU/L) | 46.11±47.48 | 60.82±66.04 | 50.51±54.09 | 0.001 |
| ALT (IU/L) | 41.73±38.55 | 56.46±75.00 | 46.13±52.58 | 0.001 |
| AlkP (IU/L) | 205.01±148.65 | 203.61±136.81 | 204.59±145.14 | 0.443 |
| Cr (mg/dL) | 1.23±1.12 | 1.56±1.34 | 1.33±1.20 | 0.001 |
| Urea (mg/dL) | 42.98±32.62 | 62.85±54.98 | 48.92±41.60 | 0.001 |
| PT (sec) | 14.13±3.97 | 14.49±4.29 | 14.24±4.07 | 0.111 |
| PTT (sec) | 37.73±11.04 | 41.85±14.50 | 38.97±12.31 | 0.101 |
| INR | 1.14±0.35 | 1.17±0.38 | 1.15±0.36 | 0.126 |
| Na (mEq/L) | 140.14±3.94 | 141.07±4.46 | 140.32±4.12 | 0.301 |
| K (mEq/L) | 4.24±0.47 | 4.30±0.46 | 4.26±0.46 | 0.231 |
| pH | 7.40±0.03 | 7.39±0.03 | 7.40±0.03 | 0.150 |
| HCO₃⁻ (mEq/L) | 25.13±6.66 | 24.71±6.60 | 25.01±6.64 | 0.179 |
| PaCO₂ (mmHg) | 41.48±12.61 | 43.12±13.74 | 41.97±12.97 | 0.835 |

* Data were analyzed using Independent-Sample t Test and Chi-Square and presented as mean ± SD and frequency (%).

** WBC: White Blood Cell; Hb: Hemoglobin; Plt: Platelet; AST: Aspartate aminotransferase; ALT: Alanine transaminase; AlkP: Alkaline Phosphatase; Cr: Creatinine; PT: Prothrombin Time; PTT: Partial Thromboplastin Time; INR: International Normalized Ratio; Na: Sodium; K: Potassium; CRP: C-Reactive Protein.

This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: http://journals.sbmu.ac.ir/aaem
Table 3: Univariate logistic regression analysis of COVID-19 mortality risk factors

| Variable               | Alive (n=701) | Dead (n=299) | OR (95% CI)        | P       |
|------------------------|--------------|--------------|--------------------|---------|
| **Age (year)**         |              |              |                    |         |
| < 60                   | 390 (55.6)   | 150 (50.2)   | -                  | 0.096   |
| 60 - 80                | 260 (37.1)   | 111 (37.1)   | 1.754 (0.932 - 3.304) | 0.082   |
| > 80                   | 51 (7.3)     | 38 (12.7)    | 2.340 (0.892 - 6.138) | 0.084   |
| **RR (/minute)**       |              |              |                    |         |
| > 20                   | 5 (1.6)      | 2 (1.7)      | 0.747 (0.106 - 5.282) | 0.770   |
| **Hospitalizations (day)** |          |              |                    |         |
| < 5                    | 647 (93)     | 233 (80.1)   | -                  | 0.001   |
| 5 - 10                 | 40 (5.7)     | 49 (16.8)    | 4.401 (1.955 - 9.906) | 0.001   |
| > 10                   | 9 (1.3)      | 9 (3.1)      | 4.006 (0.843 - 19.043) | 0.081   |
| **WBC (Cells*10^3/mL)** |            |              |                    |         |
| < 4                    | 56 (8.0)     | 56 (18.7)    | 0.717 (0.212 - 1.989) | 0.016   |
| 4 - 10                 | 531 (75.7)   | 170 (56.9)   | 0.295 (0.128 - 0.687) | 0.004   |
| > 10                   | 114 (16.3)   | 73 (24.4)    | 0.354 (0.121 - 1.034) | 0.058   |
| **Neutrophil (%)**     |              |              |                    |         |
| < 18                   | 0            | 0            | -                  | -       |
| 18 - 63                | 69 (9.8)     | 12 (4.0)     | -                  | -       |
| > 63                   | 632 (90.2)   | 287 (96.0)   | 0.625 (0.205 - 1.908) | 0.409   |
| **AST (IU/L)**         |              |              |                    |         |
| > 40                   | 209 (29.8)   | 151 (50.5)   | 6.190 (3.170 - 12.085) | 0.001   |
| **ALT (IU/L)**         |              |              |                    |         |
| > 40                   | 305 (43.5)   | 121 (40.5)   | 0.287 (0.141 - 0.582) | 0.001   |
| **Creatinine (mg/dL)** |              |              |                    |         |
| > 1.4                  | 96 (13.7)    | 77 (25.8)    | 2.673 (1.313 - 5.444) | 0.007   |
| **Urea (mg/dL)**       |              |              |                    |         |
| > 100                  | 38 (5.4)     | 54 (18.1)    | 2.764 (1.146 - 6.688) | 0.024   |
| **O2 Saturation (%)**  |              |              |                    |         |
| < 60                   | 0 (0.0)      | 0 (0.0)      | -                  | -       |
| 60 - 80                | 37 (5.3)     | 102 (34.1)   | 1.289 (0.891 - 4.313) | 0.003   |
| > 80                   | 664 (94.7)   | 197 (65.9)   | 0.095 (0.039 - 0.228) | 0.001   |

* Data are presented as frequency (%). CI: confidence interval; OR: Odds Ratio; RR: Respiratory rate; WBC: White blood cells; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.

Table 4: Multivariate logistic regression analysis of COVID-19 mortality risk factors

| Variable               | OR (95% CI)        | P-value |
|------------------------|--------------------|---------|
| Hospitalization > 5 Days | 3.47 (1.272 - 9.479) | 0.015   |
| AST > 40 IU/L          | 0.269 (0.179 - 0.402) | 0.001   |
| Creatinine > 1.4 mg/dL | 0.529 (0.344 - 0.813) | 0.004   |
| Urea > 100 mg/dL       | 0.327 (0.189 - 0.567) | 0.001   |
| SPO2 < 80%             | 8.754 (5.413 - 14.156) | 0.001   |

OR: odds ratio; CI: confidence interval; AST: Aspartate aminotransferase.

Table 5: Diagnostic value of independent risk factors of COVID-19 mortality

| Variable               | AUC (95% CI)        | P-value | Cut off point | Sensitivity | Specificity |
|------------------------|--------------------|---------|---------------|-------------|-------------|
| Hospitalization        | 0.484 (0.443-0.526) | 0.439   | -             | -           | -           |
| AST                    | 0.374 (0.328-0.403) | 0.001   | 36.5          | 61.9        | 57.8        |
| Creatinine             | 0.366 (0.325-0.414) | 0.001   | 1.05          | 48.8        | 69.4        |
| Urea                   | 0.402 (0.362-0.442) | 0.001   | 71            | 29.6        | 89.4        |
| SPO2                   | 0.705 (0.666-0.745) | 0.001   | 85.5          | 67.7        | 56.3        |

AUC: area under the receiver operating characteristic curve; CI: confidence interval; AST: Aspartate aminotransferase.

that the above variables in COVID-19 patients admitted to the ICU are good predictors of mortality (24).

This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: http://journals.sbmu.ac.ir/aaem
In recent studies, the nutritional status of patients with COVID-19 with severe disease was evaluated using mNUTRIC criteria at the time of hospitalization, and the results showed that the risk of mortality in patients with high nutritional risk, based on the above criteria, is twice as high as patients with low nutritional risk (25). However, in the present study, the nutritional status of the patients was not studied, and it is better to be considered in future studies.

By comparing the present study's findings with previous studies, we can say that the clinical and paraclinical characteristics of patients and risk factors are different, which seems to be due to differences in the number of samples, demographic characteristics, and status of patients on admission. In addition, logistic regression and ROC curve analyses were used to identify the factors affecting inpatient mortality. However, risk regression models or standard Cox proportional hazard models were used in some of the other studies (26, 27). Another reason for the difference between the present study and other studies is the age of the patients. In the present study, young and middle-aged patients were studied, while in other studies, elderly patients with a mean age over 60 years were studied (22, 24, 25, 28-30).

In a multicenter study conducted by Gupta et al. on 2215 patients in the United States, nine risk factors (including age, sex, BMI, coronary artery disease (CAD), active cancers, hypoxemia, hepatic impairment, renal impairment, and the number of hospital ICU beds) were introduced as predictors of 28-day patient mortality (29). In the present study, SPO2, Urea, creatinine, AST, and hospitalization were the factors that predicted the mortality of patients. In contrast, studies have used non-COVID-19 predictive criteria, including the Waterlow score, to predict short-term mortality and length of hospital stay in elderly patients. Waterlow score is a multidimensional criterion for evaluating bed sores, calculated based on age, nutritional status, weight, patient movement, sex, smoking, comorbidities, and medications used (30).

5. Limitations and strengths

One of the strengths of this study is the large sample size and evaluation of demographic variables, vital signs, and laboratory findings of patients with COVID-19. In addition, the assessment of mortality risk in patients based on patients’ clinical and laboratory findings also increases the applicability of the results of the present study to other patients. Limitations of the present study include: Some of the patients’ tests were not completely performed and they were excluded from the study. Some patients were discharged against medical advice or referred to other centers, and their information could not be fully verified and they were excluded from the study. Also, we didn’t evaluate and report the severity of disease.

6. Conclusion

The mortality rate of patients with COVID-19 in our study was 29.9%. Hospitalization of more than five days, AST above 40 IU/L, creatinine above 1.4 mg/dL, urea above 100 mg/dL, and SaO2 < 80% were the independent risk factors of in-hospital mortality of patients with COVID-19.

7. Declarations

7.1. Acknowledgments

The researchers acknowledge all study participants and staff of the toxicology ward in the Hospitals for their support from the beginning to the end of the research process.

7.2. Data availability

It can be available after legal permits.

7.3. Authors’ contributions

All authors participated in the conception and design, acquisition of data, analysis and interpretation of data, drafting of the article, review of the article, and finding approval.

7.4. Funding and supports

None.

7.5. Conflict of interest

No potential and actual conflicts of interest were present during our investigation.

References

1. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323(8):709-10.

2. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology. 2020;5(4):536-44.

3. Huang C, Wang Y, LiX, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.

4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.

5. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13.
6. Schlagenhauf P, Ashra H. Severe acute respiratory syndrome spreads worldwide. The Lancet. 2003;361(9362):1017.

7. Team WHOER. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. NEJM. 2014;371(16):1481-95.

8. Viboud C, Simonsen L. Global mortality of 2009 pandemic influenza A H1N1. Lancet Infect Dis. 2012;12(9):651-3.

9. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng P-Y, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687-95.

10. Nicholls JM, Poon LLM, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. The Lancet. 2003;361(9371):1773-8.

11. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223):514-23.

12. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet. 2020;395(10225):689-97.

13. Mahase E. Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ. 2020. 368:m641.

14. Altschul DJ, Unda SR, Benton J, de la Garza Ramos R, Cezayiri P, Mehler M, et al. A novel severity score to predict inpatient mortality in COVID-19 patients. Sci Rep. 2020;10(1):1-8.

15. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180(8):1081-9.

16. Pan P, Li Y, Xiao Y, Han B, Su L, Su M, et al. Prognostic assessment of COVID-19 in the intensive care unit by machine learning methods: model development and validation. J Med Internet Res. 2020;22(11):e23128.

17. Richardson S, Hirsch JS, Narasimhan M, Crawford MJ, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9.

18. Zhou F, Yinfeng D, Wei J, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-62.

19. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict inpatient mortality in COVID-19 patients. Sci Rep. 2020;10(1):1-8.

20. Fumagalli C, Rozzini R, Vannini M, Coccia F, Cesaroni G, Mazzeo F, et al. Clinical risk score to predict in-hospital mortality and recovery: A pitfall in COVID-19 survival analysis research. medRxiv. 2020;20200711.20151472.

21. Zhao Z, Chen A, Hou W, Graham JM, Li H, Richman DS, et al. Prediction model and risk scores of ICU admission and mortality in COVID-19. PloS one. 2020;15(7):e0236618.

22. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180(11):1436-47.

23. Wang JW, Smith P, Sarker S-J, Elends S, Oliveira A, Barritt C, et al. Can Waterlow score predict 30-day mortality and length of stay in acutely admitted medical patients (aged≥65 years)? Evidence from a single centre prospective cohort study. BMJ open. 2019;9(11):e032347.